PREEMTIVE ANALGESIC EFFICACY OF INTRAMUSCULAR PARECOXIB SODIUM VERSUS KETOROLAC FOR THIRD MOLAR SURGICAL REMOVAL: A PILOT STUDY

Abstract

The objective of this research was to compare the preemptive analgesic efficacy of intramuscular Parecoxib sodium versus Ketorolac in patients undergoing third molar surgical removal. This is a pilot clinical research study, double-blinded and split-mouth technique. There were 10 participants divided into two groups: Group A was premedication with Ketorolac 30 mg. before the first operation and with Parecoxib sodium 20 mg. before the second operation, and Group B was premedication with Parecoxib sodium 20 mg. before the first operation and Ketorolac 30 mg. before the second operation. Participants will receive a medication injection in the deltoid muscle 15 minutes before the surgery. Pain assessment is conducted using the Visual Analog Scale (VAS) 2, 4, 6, 8, 10, 12, and 24 hours after undergoing third molar surgical removal. If the patient experiences pain, they are administered one Tramadol 50 mg rescue medication, and the time and quantity of medication taken are recorded. Results of this research indicate that Parecoxib and Ketorolac provide preemptive analgesic efficacy after lower third molar surgery with no significant difference. However, Parecoxib significantly reduces pain levels more than Ketorolac at the 24-hour postoperatively. Therefore, administering Parecoxib offers more effective and longer-lasting pain relief compared to Ketorolac in patients undergoing lower third molar surgery. However, due to the small sample size, the findings cannot be generalized.